Zhang et al., used a modified Herpes simplex strain (oHSV) which, when paired with anti CTLA and anti OX40 monoclonal antibodies (MAbs), managed to activate the host immune response against cancer cells, in a proinflammatory type 1 immune response (augmented antitumoral TAMs and effector T cells, and decreased regulatory T cells). Here, TNFRSF4 is linked to cancer.